ESMO 2024 | VOLGA: impact of ctDNA clearance on survival outcomes in bladder cancer
Alexandra Drakaki, MD, PhD, University of California Los Angeles, Los Angeles, CA, presents findings from the Phase III VOLGA trial (NCT04960709), which demonstrated that majority of patients were initially positive for circulating tumor DNA (ctDNA). Following neoadjuvant therapy with durvalumab, tremelimumab, and enfortumab vedotin, there was a significant increase in ctDNA negativity, with many patients achieving ctDNA clearance and pathological complete response (CR). Patients who were ctDNA negative at baseline or after neoadjuvant therapy also experienced prolonged event-free survival (EFS) compared to those who remained ctDNA positive, underscoring the prognostic significance of ctDNA dynamics in treatment response. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
